Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The EMA at 20: CHMP chair on HTA, patient involvement and dealing with uncertainty

This article was originally published in SRA

Executive Summary

Getting Europe's diverse member states together to evaluate and manage human medicines was a tall order when the European Medicines Agency was created 20 years ago. It can still seem that way today. Tomas Salmonson, the chair of the EMA's Committee for Medicinal Products for Human Use, talks to Francesca Bruce* about the challenges of reaching consensus, evaluating drugs with little data, and getting patients more closely involved.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS118136

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel